source
- Biogen’s experimental Alzheimer’s drug diranersen slows cognitive decline in Phase 2, matching approved therapiesBiogen reported that its experimental Alzheimer’s therapy diranersen slowed cognitive decline in a mid-stage Phase 2 study, achieving decline rates similar to those seen with drugs already on the m…
- Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trialBiogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…